fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Midazolam

All injection strengths: Limited Use (codes 495, 496)

Midazolam Injection · DIN 02240286 · 5 mg/mL · injection solution (with Preservative)

Limited Use, Reason for Use code 495, 496 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 495, 496 required
Write on scriptone applicable Reason for Use code, 495 or 496 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 495, 496
Reason for Use code 495 For intermittent injection used for symptomatic relief in patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes. Reason for Use code 496 For continuous infusion in patients receiving palliative sedation*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Midazolam Injection · DIN 02240286 Manufacturer: Sandoz Canada Inc.; listing date 2017-05-31 Health Canada: Marketed since 2005-10-06 · brand MIDAZOLAM INJECTION · ATC N05CD08 MIDAZOLAM · form Solution · route Intravenous, Intramuscular · ingredients MIDAZOLAM 5 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)
Re-check Health Canada status and shortages (live) · Health Canada product record

Midazolam Injection: Formulary list price $4.10 per unit (the source does not state the unit; exact figure $4.1000). What the ministry pays, not the patient.

Ministry pays: $4.1000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240286)

Source record
DIN 02240286: Midazolam Injection Raw flags: sec12=Y, sec3=Y Item: 282400180; group id 525; item number 1421; lccId 00284; manufacturer id SDZ Source form: Inj Sol (with Preservative); strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.1000; ministry $4.1000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240286 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63824
Interchangeable products
Midazolam Injection · DIN 02242905 · $4.1000 Versed · DIN 00766011 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (N05C, N05CD): coverage varies; not interchangeable

  • Flurazepam (Dalmane): general benefit, not a benefit
  • Nitrazepam (Mogadon): general benefit
  • Temazepam (Restoril): general benefit
  • Triazolam (Halcion): general benefit, not a benefit
  • Eszopiclone (Lunesta): not a benefit
  • Zolpidem (Sublinox): not a benefit

1 more in the class list below

Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit (38), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2) · strengths: 3.75mg, 5mg, 7.5mg · Tab

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MIDAZOLAM INJECTION (midazolam) is indicated as: • an intramuscular premedication prior to surgical or diagnostic procedures. • an intravenous agent for patients requiring sedation/anxiolysis/amnesia prior to and during short endoscopic or short diagnostic procedures and direct-current cardioversion. • an alternative intravenous agent for the induction of anesthesia. • a continuous intravenous infusion in intubated, mechanically ventilated patients requiring sedation in the Intensive Care Unit (ICU). 1.1 Pediatrics Pediatrics (<18 years old): Health Canada has authorized an indication for pediatric use of MIDAZOLAM INJECTION for: • sedation, anxiolysis, and/or amnesia for diagnostic or therapeutic procedures • preanesthesia • a component of anesthesia during surgical procedures, or during treatment in critical care settings. (see 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment; 7.1.3 Pediatrics) 1.2 Geriatrics Geriatrics (>55 years old): Evidence suggests that use in the geriatric population is associated with differences in safety or effectiveness. Intravenous sedation with MIDAZOLAM IN… https://pdf.hres.ca/dpd_pm/00083597.PDF PM date: July 21, 1999 Source product: MIDAZOLAM INJECTION; DIN 02240286; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.